Significant Ownership of NOVARTIS PHARMA AG
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for NOVARTIS PHARMA AG focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Christian Rehm - Christian Rehm / Authorised Signatory
- Manager location
- Basel, Switzerland
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow NOVARTIS PHARMA AG with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from NOVARTIS PHARMA AG
Significant Ownership of NOVARTIS PHARMA AG
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ERAS | Erasca, Inc. | Common stock, par value $0.0001 per share | 4.4% | $17,107,692 | 12,307,692 | Novartis Pharma AG | 31 Dec 2024 | ||
| DTIL | PRECISION BIOSCIENCES INC | Common stock, par value $0.000005 per share | 3.7% | $1,840,435 | 413,581 | 0% | Novartis Pharma AG | 30 Jun 2025 |
Schedules 13D/G Reported by NOVARTIS PHARMA AG:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.